Skip to main content
Erschienen in: World Journal of Surgical Oncology 1/2024

Open Access 01.12.2024 | Research

Preoperative predictors for non-resectability in perihilar cholangiocarcinoma

verfasst von: Carlos Constantin Otto, Anna Mantas, Lara Rosaline Heij, Daniel Heise, Maxime Dewulf, Sven Arke Lang, Tom Florian Ulmer, Edgar Dahl, Philipp Bruners, Ulf Peter Neumann, Jan Bednarsch

Erschienen in: World Journal of Surgical Oncology | Ausgabe 1/2024

Abstract

Introduction

Explorative laparotomy without subsequent curative-intent liver resection remains a major clinical problem in the treatment of perihilar cholangiocarcinoma (pCCA). Thus, we aimed to identify preoperative risk factors for non-resectability of pCCA patients.

Material and methods

Patients undergoing surgical exploration between 2010 and 2022 were eligible for the analysis. Separate binary logistic regressions analyses were used to determine risk factors for non-resectability after explorative laparotomy due to technical (tumor extent, vessel infiltration) and oncological (peritoneal carcinomatosis, distant nodal or liver metastases)/liver function reasons.

Results

This monocentric cohort comprised 318 patients with 209 (65.7%) being surgically resected and 109 (34.3%) being surgically explored [explorative laparotomy: 87 (27.4%), laparoscopic exploration: 22 (6.9%)]. The median age in the cohort was 69 years (range 60–75) and a majority had significant comorbidities with ASA-Score ≥ 3 (202/318, 63.5%). Statistically significant (p < 0.05) risk factors for non-resectability were age above 70 years (HR = 3.76, p = 0.003), portal vein embolization (PVE, HR = 5.73, p = 0.007), and arterial infiltration > 180° (HR = 8.05 p < 0.001) for technical non-resectability and PVE (HR = 4.67, p = 0.018), arterial infiltration > 180° (HR = 3.24, p = 0.015), and elevated CA 19–9 (HR = 3.2, p = 0.009) for oncological/liver-functional non-resectability.

Conclusion

Advanced age, PVE, arterial infiltration, and elevated CA19-9 are major risk factors for non-resectability in pCCA. Preoperative assessment of those factors is crucial for better therapeutical pathways. Diagnostic laparoscopy, especially in high-risk situations, should be used to reduce the amount of explorative laparotomies without subsequent liver resection.
Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1186/​s12957-024-03329-1.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ALPPS
Associating liver partition and portal vein ligation for staged hepatectomy
ALT
Alanine aminotransferase
AP
Alkaline phosphatase
ASA
American Society of Anesthesiologists
AST
Aspartate aminotransferase
BMI
Body mass index
CA 19-9
Carbohydrate antigen 19–9
CCA
Cholangiocellular carcinoma
CI
Confidence interval
CRP
C reactive protein
CSS
Cancer-specific survival
CT
Computed tomography
CUSA
Cavitron Ultrasonic Surgical Aspirator
EBD
Endoscopic biliary drainage
ERCP
Endoscopic retrograde cholangiopancreatography
FFP
Fresh frozen plasma
FLR
Future liver remnant
GGT
Gamma-glutamyltransferase
INR
International normalized ratio
LiMAx
Maximum liver function capacity
MIRLS
Minimally invasive robotic liver surgery
MRCP
Magnetic resonance cholangiopancreatography
MRI
Magnetic resonance imaging
PBD
Percutaneous biliary drainage
PET-CT
Positron emission tomography–computed tomography
PVE
Portal vein embolization
PHLF
Post hepatectomy liver failure
pCCA
Perihilar cholangiocarcinoma
RWTH
Rheinisch-Westfälische Technische Hochschule

Introduction

Perihilar cholangiocarcinoma (pCCA) is the most common subtype of CCA, usually diagnosed in the advanced disease stage and mostly associated with poor oncological outcomes [1]. Liver resection remains the gold standard of therapy and the only option for long-term survival in patients with pCCA [2]. Over the last decades, surgical therapy has evolved from isolated resection of the extrahepatic bile duct to extended liver resection with vascular reconstructions as well as multivisceral resections resulting in increased resectability rates for patients with advanced pCCA [39]. Unfortunately, recurrence rates after curative intent surgery remain high [10]. Surgical margin, lymph node status, tumor differentiation as well as the involvement of vessels are the main prognostic factors for oncological outcomes after curative-intent surgery [11]. In case of irresectability due to cirrhosis or technical concerns, a small proportion of patients who are no candidates for resection might also be applicable to curative-intent therapy by transplantation after neoadjuvant therapy. Of note, the assessment for transplantation is strictly characterized by adherence to regulative protocols, e.g., the Mayo protocol [12]. However, most patients diagnosed with pCCA are not eligible for operative resection at the time of diagnosis due to distant metastasis or extensive vascular involvement at the liver hilum [1, 13, 14].
Despite the improvement of numerous preoperative imaging modalities, e.g., multiphase computer tomography (CT), magnetic resonance cholangiopancreatography (MRCP)/magnetic resonance imaging (MRI) and positron emission tomography (PET)–CT, a notable amount undergoes surgical exploration and is intraoperatively assessed as not being resectable due to surgical reasons (infiltration of vessels, etc.), impaired liver function or previously undetected peritoneal carcinomatosis and distant lymph node metastases [1, 13]. At this point, there is no staging system sufficiently predicting resectability in pCCA [15].
Surgical exploration is associated with significant cost, impaired quality of life, postoperative complications, unnecessary hospitalization, and a delay in systemic therapy. Therefore, we here aimed to investigate the role of surgical exploration in patients with pCCA and identify preoperative predictors for irresectability of patients with pCCA undergoing operative exploration in curative intent.

Material and methods

Patients

All consecutive patients with pCCA who underwent operative exploration with curative intent at the University Hospital RWTH Aachen (UH-RWTH) between 2010 and 2022 were included in this retrospective study. Patients diagnosed with intrahepatic cholangiocarcinoma involving the liver hilum pre- or postoperatively were not investigated in this study. This study was conducted in concordance with the requirements of the Institutional Review Board of the RWTH-Aachen University (EK 23–270) and the current version of the Declaration of Helsinki as well as the good clinical practice guidelines (ICH-GCP). The utilized data was collected retrospectively and saved in an institutional database.

Staging and surgical procedure

All included patients preoperatively underwent a detailed preoperative clinical work-up as described previously [16, 17]. To classify tumor extent, endoscopic retrograde cholangiopancreatography (ERCP) and/or magnetic resonance cholangiopancreatography (MRCP) were conducted. Carbohydrate antigen 19–9 (CA19-9) was used as a tumor marker. The anatomical classification was described according to Bismuth-Corlette. Computed tomography (CT) with arterial and venous phases was the standard procedure to rule out distant metastases and assess a possible tumor invasion of perihilar vessels as well as the vascular anatomy of the liver. The preoperative imaging was not older than 4 weeks at the time of surgical exploration in every patient. Ultrasound-directed aspiration of suspicious locoregional lymph nodes was not carried out routinely as nodal metastases in regional nodes were not considered as a contraindication for surgical resection. Diagnostic laparoscopy was only carried out if there were clear diagnostic hints for the presence of peritoneal carcinomatosis. Unilateral stenting of the future remnant liver (FLR) was preferred, only in cases with refractory cholangitis, and persistent cholestasis bilateral stenting was performed. Generally, endoscopic biliary drainage (EBD) was preferred over percutaneous biliary drainage (PBD). Based on the results of preoperative FLR prediction, right portal vein embolization (PVE) was conducted in cases with insufficient FLR scheduled for right-sided hepatectomy 2 to 4 weeks before surgery. Generally, a FLR above 30% was considered as sufficient. In selected cases with borderline FLR or risk factors of impaired parenchyma quality, e.g., neoadjuvant therapy or chronic cholestasis, maximum liver function capacity (LiMAx) was carried out to assess metabolic liver function [18]. Neoadjuvant therapy was considered in cases that were preoperatively assessed as non-resectable or in cases with distant lymph node metastases. Furthermore, the classification of the American Society of Anesthesiologists (ASA) was used to objectify patients´ preoperative status. The decision for primary surgery was always made by an experienced hepatobiliary surgeon in accordance with the interdisciplinary tumor board. During surgical exploration, the resectability of the tumor was assessed by an experienced hepatobiliary surgeon. If resectability was ensured, liver resection with lymphadenectomy was carried out as previously described [19, 20]. Specimens were examined by an experienced pathologist both for intraoperative frozen sections as well as for the final tissue diagnosis.

Reasons for non-resectability

During surgical exploration, the peritoneal cavity was meticulously examined for peritoneal carcinomatosis, liver metastases, or distant lymph node metastasis. If any of these observations were detected and verified by intraoperative frozen sections, liver resection was not pursued. Secondly, the quality of the liver parenchyma was assessed by inspection. If in contradiction to the preoperative evaluation the assumed liver function of the FLR was considered insufficient, the surgical procedure was also terminated. Also, in the case of an intraoperatively smaller FLR as initially planned e. g. due to the necessity to remove more liver volume or segments to achieve clear tumor margins, the procedure was terminated. Afterward, the liver hilum was also carefully explored by the attending surgeon. Here, technical reasons for non-resectability were assessed. The main reasons for technical non-resectability were tumor infiltration of major vessels without the possibility of reconstruction and unexpected tumor growth precluding an R0 resection. Furthermore, a larger tumor extent than expected resulting in a more extensive surgical procedure than planned (e.g., hepatopancreaticoduodenectomy or trisectionectomy instead of conventional left or right hepatectomy), was considered a contraindication if the patient’s physical fitness did not allow an escalation of the surgical procedure.

Follow-up

After surgical resection, adjuvant therapy was recommended in cases of high-risk features (e.g., positive nodal status, R1 resection) between 2010 and 2017 in and after 2017 in any case according to the results of the BILCAP trial [21]. In patients who were considered not resectable, palliative systemic treatment was proposed to all patients during the study period.

Statistical analysis

Categorical data are reported as absolute numbers and percentages. Continuous variables are displayed by median and interquartile range. The primary endpoint of our study was the identification of preoperative parameters associated with non-resectability for various reasons. Those parameters were identified by univariate and multivariable logistic regression analysis between patients being successfully resected and patients undergoing exploration without resection. Only statistically significant parameters (p < 0.05) in univariable analysis were subsequently analyzed with multivariable binary logistic regressions using backward elimination. Separate analyses were conducted for patients being non-resectable due to oncological/liver function and technical reasons. The secondary endpoint of the study was the comparison of cancer-specific survival (CSS) between resected and non-resected patients. CSS was defined as the time between the date of operation and the date of last contact (if the patient was still alive) or the date of tumor-related death. Survival curves were generated by the Kaplan–Meier method and compared with the log-rank test. Median follow-up was assessed using the reverse Kaplan–Meier method. Statistical significance was set at p ≤ 0.05. Confidence level is set to 95%. Analyses were performed with SPSS Statistics 24 (IBM Corp., Armonk, NY, USA).

Results

Patient cohort

The cohort consisted of 318 patients who underwent surgical exploration for pCCA in curative intent between 2010 and 2022 at our institution. The overall cohort was based on 206 male (64.8%) and 112 female patients (35.2%) with a median age of 69 years (range 60–75). Most of the patients had significant comorbidity with ASA-Score ≥ 3 (202/318, 63.5%). Bismuth type IV represented the most frequent pCCA type (96/318, 30.2%), followed by Bismuth Type IIIa (86/318, 27%) and Bismuth Type IIIb (69/318, 21.7%). A subset of 18 patients (5.7%) underwent neoadjuvant chemotherapy. Tumor infiltration of portal vein (145/318, 45.7%) or hepatic artery (83/318, 26.2%) was widely observed in the preoperative radiologic imaging.
The cohort was divided into groups for further analysis: The majority of patients successfully underwent oncological resection of the tumor (“resected cohort”, 209/318, 65.7%), while the remaining patients underwent either conventional or laparoscopic exploration and were considered not resectable (“overall exploration cohort”, 109/318, 34.3%). The overall exploration group was further used for survival analysis to determine the oncological role of non-resectability. The subgroup of patients who were explored by explorative laparotomy was further used for regression analysis to determine the role of unnecessary surgical laparotomies (explorative laparotomy group (87/318, 27.4%). Patients undergoing surgical exploration without resection who were later resected after chemotherapy or other optimization methods were not allocated to the exploration but resection cohort.
The most frequent reasons for non-resectability in the overall cohort were peritoneal carcinomatosis (46/109, 42.2%), vascular infiltration (20/109, 18.3%), a larger resection extent than expected (14/109, 12.8%), distant lymph node metastases (12/109, 11.0%), impaired liver function/liver cirrhosis (9/109, 8.3%), and liver metastases (5/109, 4.6%).
Detailed demographic and clinicopathological statistics of the relevant subcohorts are displayed in Table 1.
Table 1
Patients’ characteristics
Demographics
Resected cohort (n = 209)
Overall exploration (n = 109)
Exploration without laparoscopy (n = 87)
Gender, m/f (%)
139 (66.5)/70 (33.5)
67 (61.5)/42 (38.5)
51 (58.6)/36 (41.4)
Age (years)
68 (58–74)
70 (62–76)
72 (64–76)
BMI (kg/m2)
25.3 (22.8–28.4)
25.5 (22.9–28.8)
25.4 (22.6–28.9)
Bismuth classification, n (%)
 I
11 (5.3)
7 (6.4)
7 (8)
 II
28 (13.4)
20 (18.3)
16 (18.4)
 IIIa
61 (29.2)
25 (22.9)
18 (20.7)
 IIIb
51 (24.4)
18 (16.5)
15 (17.2)
 IV
57 (27.3)
39 (35.8)
31 (35.6)
Neoadjuvant therapy, n (%)
10 (4.8)
8 (7.3)
5 (5.7)
Portal vein embolization, n (%)
74 (35.4)
18 (16.5)
14 (16.1)
ASA, n (%)
 I
8 (3.8)
4 (3.7)
2 (2.3)
 II
71 (34)
33 (30.3)
25 (28.7)
 III
116 (55.5)
66 (60.6)
55 (63.2)
 IV
14 (6.7)
6 (5.5)
5 (5.7)
 V
0
0
0
Preoperative cholangitis, n (%)
67 (32.1)
27 (24.8)
31 (35.6)
Preoperative EBD, n (%)
150 (71.8)
80 (73.4)
63 (72.4)
Preoperative PBD, n (%)
52 (24.9)
27 (24.8)
25 (28.7)
Portal vein infiltration > 180°, n (%)
 None
117 (56)
55 (50.5)
43 (49.4)
 Main
3 (1.4)
23 (21.1)
19 (21.8)
 Bifurcation
27 (12.9)
0
0
 Right
22 (10.5)
9 (8.3)
8 (9.2)
 Left
38 (18.2)
22 (20.2)
17 (19.5)
 Right and left
1 (0.5)
0
0
Arterial infiltration > 180°, n (%)
 None
169 (80.9)
65 (59.6)
51 (58.6)
 Main
0
15 (13.8)
12 (13.8)
 Bifurcation
0
0
0
 Right
34 (16.3)
25 (22.9)
21 (24.1)
 Left
3 (1.4)
4 (3.7)
3 (3.4)
 Right and left
2 (1)
0
0
Lobar atrophy, n (%)
 None
146 (69.9)
78 (71.6)
61 (70.1)
 Right
9 (4.3)
2 (1.8)
2 (2.3)
 Left
53 (25.4)
29 (26.6)
24 (27.6)
sFLR (%)
0.57 (0.39–0.72)
0.56 (0.44–0.7)
0.55 (0.43–0.67)
Clinical chemistry
 Albumin (g/dl)
3.8 (3.4–4.1)
3.7 (3.2–4.2)
3.7 (3.2–4.1)
 AST (U/l)
45 (34–84)
52 (31–79)
48 (30–79)
 ALT (U/l)
58 (35–111)
55 (32–100)
54 (28–101)
 GGT (U/l)
403 (188–758)
394 (182–739)
393 (170–733)
 Total bilirubin (mg/dl)
1.1 (0.6–2.8)
1.3 (0.8–3.2)
1.4 (0.8–3.2)
 Platelet count (/nl)
295 (228–389)
278 (215–355)
281 (240–354)
 Alkaline phosphatase (U/l)
266 (158–423)
251 (158–457)
247 (157–441)
 Prothrombin time (%)
96 (84–105)
92 (77–102)
92 (75–102)
 INR
1.03 (0.97–1.11)
1.05 (0.97–1.16)
1.05 (0.97–1.19)
 Hemoglobin (g/dl)
12.2 (11–13.3)
12.3 (10.8–13.5)
12.4 (10.9–13.4)
 CRP (mg/l)
12 (6–35.8)
18.9 (7.2–45.1)
19.4 (7–43)
 CA 19–9 (U/ml)
99 (34–335)
293 (78–1387)
231 (79–1135)
Operative data
 Operative time (minutes)
450 (379–511)
120 (118.5–122.5)
120 (120–136)
 Operative procedure, n (%)
   Limited bile duct resection
8 (3.8)
n.a
n.a
  Right hepatectomy
26 (12.4)
n.a
n.a
  Left hepatectomy
28 (13.4)
n.a
n.a
   Mesohepatectomy
2 (1)
n.a
n.a
  Extended right hepatectomy
42 (20.1)
n.a
n.a
  Extended left hepatectomy
53 (25.4)
n.a
n.a
   Right trisectionectomy
26 (12.4)
n.a
n.a
   Left trisectionectomy
9 (4.3)
n.a
n.a
   Hepatoduodenoectomy
13 (6.2)
n.a
n.a
  ALPPS
0
n.a
n.a
 Reasons for irresectability
  Liver function/Liver cirrhosis
n.a
9 (8.3)
5 (5.7)
  Distant lymph nodes
n.a
12 (11)
12 (13.8)
  Liver metastases
n.a
5 (4.6)
2 (2.3)
  Peritoneal carcinomatosis
n.a
46 (42.2)
33 (37.9)
   Vascular infiltration without
n.a
20 (18.3)
20 (23)
   Possibility of reconstruction
   
   Resection larger than expected
n.a
14 (12.8)
13 (14.9)
  Others
n.a
3 (2.8)
2 (2.3)
 Portal vein reconstruction
152 (72.7)
n.a
n.a
 Arterial reconstruction
16 (7.7)
n.a
n.a
 Intraoperative PRBC
104 (49.8)
0
0
 Intraoperative FFP
113 (54.1)
0
0
Pathological examination
 R1 resection, n (%)
40 (19.1)
n.a
n.a
 pT category, n (%)
 
n.a
n.a
  1
15 (7.2)
n.a
n.a
  2
116 (55.5)
n.a
n.a
  3
51 (24.4)
n.a
n.a
  4
19 (9.1)
n.a
n.a
 pN category
  N0
116 (55.5)
n.a
n.a
  N1
92 (44)
n.a
n.a
 Tumor grading, n (%)
  G1
8 (3.8)
n.a
n.a
  G2
138 (66)
n.a
n.a
  G3
49 (23.4)
n.a
n.a
  G4
1 (0.5)
n.a
n.a
 MVI, n (%)
62 (29.7)
n.a
n.a
 LVI, n (%)
46 (22)
n.a
n.a
 PNI, n (%)
147 (70.3)
n.a
n.a
Postoperative data
 Intensive care, days
2 (1–5)
0
0
 Hospitalization, days
19 (12–35)
9 (5–21)
12 (6–22)
 Postoperative complications, n (%)
   No complications
35 (16.7)
66 (60.6)
49 (56.3)
  Clavien-Dindo I
12 (5.7)
9 (8.3)
8 (9.2)
  Clavien-Dindo II
43 (20.1)
6 (5.5)
4 (4.6)
   Clavien-Dindo IIIa
36 (17.2)
14 (12.8)
12 (13.8)
  Clavien-Dindo IIIb
34 (16.3)
3 (2.8)
3 (3.4)
  Clavien-Dindo Iva
11 (5.3)
2 (1.8)
2 (2.3)
  Clavien-Dindo Ivb
7 (3.3)
0
0
  Clavien-Dindo V
32 (15.3)
9 (8.3)
9 (10.3)
Oncologic dataa
 Adjuvant therapy
57 (27.3)
n.a
n.a
 Median CSS, months (95% CI)
 32 (20-44)
6 (4–8) 
 n.a
Data presented as median and interquartile range if not noted otherwise
ALT Alanine aminotransferase, ASA American Society of Anesthesiologists classification, AST Aspartate aminotransferase, BMI Body mass index, CCI Comprehensive complication index, CSS Cancer-specific survival, EBD Endoscopic biliary drainage, FFP Fresh frozen plasma, pCCA Perihilar cholangiocarcinoma, GGT Gamma-glutamyltransferase, INR International normalized ratio, LVI Lympho-vascular invasion, MVI Microvascular invasion, PBD Percutaneous biliary drainage, PNI Perineural invasion, PRBC Packed red blood cells
aOncologic data with the exclusion of perioperative mortality

Logistic regression analyses for explorative laparotomy

As we aimed to primarily investigate unnecessary laparotomies, patients who were determined as not resectable by laparoscopy were excluded from the logistic regression analysis. We assessed risk factors for non-resectability due to technical reasons (vascular infiltration without the possibility of reconstruction or resection larger than expected). Therefore, those patients were investigated together with the resected cohort using univariate binary logistic regressions for explorative laparotomy as described in the given literature [22]. Parameters with a p value < 0.05 were defined as statistically relevant. In here, relevant risk factors were age above 70 years (hazard ratio (HR) = 2.43, Confidence interval (CI):1.15–5.16, p = 0.019), preoperative portal vein embolization (PVE, HR = 5.48, CI1.62–18.57, p = 0.001) and arterial infiltration of more than 180° (HR = 5.2, CI 2.41–11.22, p < 0.001). Those variables were further included in a multivariable logistic regression model to assess statistical independence. This model defined age above 70 years (HR = 3.76, CI 1.56–9.08, p = 0.003), PVE (HR = 5.73, CI 1.61–20.38, p = 0.007) and arterial infiltration > 180° (HR = 8.05, CI 3.32–19.53, p < 0.001) as independent predictors of non-resectability (Table 2).
Table 2
Logistic regression of preoperative parameters for non-resectability due to technical reasons
 
Univariate analysis
Multivariate analysis
HR (95% CI)
P value
HR (95% CI)
P value
Demographics
 Sex (male = 1)
 
0.1
  
 Age (≤ 70 years = 1)
2.43 (1.15–5.16)
0.019
3.76 (1.56–9.08)
0.003
 BMI (≤ 25 kg/m2 = 1)
 
0.561
  
 Bismuth type (I/II = 1)
 
0.087
  
 Neoadjuvant therapy (no = 1)
 
0.636
  
 Preoperative MR-Imaging (no = 1)
 
0.666
  
 PVE (no = 1)
5.48 (1.62–18.57)
0.001
5.73 (1.61–20.38)
0.007
 ASA (I/II = 1)
 
0.401
  
 Preoperative cholangitis (no = 1)
 
0.84
  
 EBD (no = 1)
 
0.909
  
 PBD (no = 1)
 
0.315
  
 Portal vein infiltration > 180° (no = 1)
 
0.139
  
 Arterial infiltration > 180° (no = 1)
5.2 (2.41–11.22)
 < 0.001
8.05 (3.32–19.53)
 < 0.001
 Lobar atrophy (no = 1)
 
0.765
  
 sFLR (≤ 40% = 1)
 
0.468
  
Clinical chemistry
 Albumin (≤ 35 g/l = 1)
 
0.353
  
 AST (≤ 50 U/l = 1)
 
0.649
  
 ALT (≤ 50 U/l = 1)
 
0.315
  
 GGT (≤ 400 U/l = 1)
 
0.263
  
 Bilirubin (≤ 1 mg/dl = 1)
 
0.921
  
 Alkaline phosphatase (≤ 250 U/l = 1)
 
0.439
  
 Platelet count (≤ 300/nl = 1)
 
0.462
  
 INR (≤ 1 = 1)
 
0.364
  
 Hemoglobin (≤ 12 g/dl = 1)
 
0.819
  
 CRP, mg/l (≤ 10 mg/l = 1)
 
0.694
  
 CA 19–9, U/ml (≤ 250 U/ml = 1)
 
0.673
  
Various parameters are associated with non-resectability. Statistically significant p values are presented in brackets
ALT Alanine aminotransferase, ASA American Society of Anesthesiologists classification, AST Aspartate aminotransferase, BMI Body mass index, CRP C-reactive protein, EBD Endoscopic biliary drainage, GGT Gamma-glutamyltransferase, INR International normalized ratio, PBD Percutaneous biliary drainage, PVE Portal vein embolization
A similar approach was used to identify risk factors for non-resectability due to oncological and liver function reasons. Cases with intraoperative diagnosed distant lymph nodes, liver metastases, or peritoneal carcinomatosis were added for oncological reasons. Non-resectability due to liver function was defined as an intraoperative diagnosis of cirrhosis. The combination of oncological and liver function reasons was chosen as these features might be also assessable by diagnostic laparoscopy. Hereby, PVE (HR = 2.62, CI 1.21–5.67, p = 0.009), arterial infiltration > 180° (HR = 2.29, CI 1.78–4.48, p = 0.017), and CA 19–9 > 250 U/ml (HR = 3.91, CI 1.71–8.93, p = 0.001) were significant in univariate logistic regression. Those parameters were further evaluated in multivariable logistic regression. In this analysis, PVE (HR = 4.67, CI 1.31–16.69, p = 0.018), arterial infiltration > 180° (HR = 3.24, CI:1.26–8.31, p = 0.015) and CA 19–9 > 250 U/ml (HR = 3.2, CI 1.33–7.69, p = 0.009) showed an independent association for non-resectability due to oncological and liver function reasons (Table 3).
Table 3
Logistic regression of preoperative parameters for non-resectability due to oncological reasons/liver function
 
Univariate analysis
Multivariate analysis
HR (95% CI)
P value
HR (95% CI)
P value
Demographics
 Sex (male = 1)
 
0.503
  
 Age (≤ 70 years = 1)
 
0.223
  
 BMI (≤ 25 kg/m2 = 1)
 
0.976
  
 Bismuth type (I/II = 1)
 
0.454
  
 Neoadjuvant therapy (no = 1)
 
0.425
  
 Preoperative MRI-Imaging (no = 1)
 
0.776
  
 PVE (no = 1)
2.62 (1.21–5.67)
0.009
4.67 (1.31–16.69)
0.018
 ASA (I/II = 1)
 
0.341
  
 Preoperative cholangitis (no = 1)
 
0,541
  
 EBD (no = 1)
 
0.93
  
 PBD (no = 1)
 
0.786
  
 Portal vein infiltration > 180° (no = 1)
 
0.575
  
 Arterial infiltration > 180° (no = 1)
2.29 (1.78–4.48)
0.017
3.24 (1.26–8.31)
0.015
 Lobar atrophy (no = 1)
 
0.687
  
 sFLR (≤ 40% = 1)
 
0.109
  
Clinical chemistry
 Albumin (≤ 35 g/l = 1)
 
0.888
  
 AST (≤ 50 U/l = 1)
 
0.239
  
 ALT (≤ 50 U/l = 1)
 
0.755
  
 GGT (≤ 400 U/l = 1)
 
0.593
  
 Bilirubin (≤ 1 mg/dl = 1)
 
0.167
  
 Alkaline phosphatase (≤ 250 U/l = 1)
 
0.678
  
 Platelet count (≤ 300/nl = 1)
 
0.521
  
 INR (≤ 1 = 1)
 
0.698
  
 Hemoglobin (≤ 12 g/dl = 1)
 
0.08
  
 CRP, mg/l (≤ 10 mg/l = 1)
 
0.404
  
 CA 19–9 U/ml (≤ 250 U/ml = 1)
3.91 (1.71–8.93)
0.001
3.2 (1.33–7.69)
0.009
Various parameters are associated with non-resectability. Statistically significant p values are presented in brackets
ALT Alanine aminotransferase, ASA American Society of Anesthesiologists classification, AST Aspartate aminotransferase, BMI Body mass index, CRP C-reactive protein, EBD Endoscopic biliary drainage, GGT Gamma-glutamyltransferase, INR International normalized ratio, PBD Percutaneous biliary drainage, PVE Portal vein embolization
Similar analyses were done excluding patients with R1 resection from the data set. Here, risk factors for non-resectability due to technical reasons were age above 70 years (HR = 3.42, CI 1.38–8.50, p = 0.008), PVE (HR = 6.41, CI 1.77–23.15, p = 0.005) and arterial infiltration of more than 180° (HR = 7.94, CI 3.16–19.94, p < 0.001) in multivariate analysis (Supplementary Table S1). For non-resectability due to oncological and liver function reasons, PVE (HR = 5.18, CI 1.43–18.80, p = 0.012), arterial infiltration > 180° (HR = 3.57, CI 1.33–9.62, p = 0.012), and CA 19–9 > 250 U/ml (HR = 3.17, CI 1.29–7.81, p = 0.012) were independently associated (Supplementary Table S2).

Survival analysis

To assess the prognostic impact of non-resectability in pCCA, survival analysis was conducted. While the median CSS was 32 months (95%CI 20–44 months) after curative liver resection, a median CCS of 6 months (95%CI 4–8 months) was observed in patients being surgically explored but not resected (p = 0.001, Fig. 1) Further, an analysis with respect to resection margin was carried out (Supplementary Figure S1).

Discussion and conclusion

Curative-intent surgery remains the mainstay of treatment for patients diagnosed with pCCA providing the best long-term prognosis among all available treatment modalities. Assessing surgical resectability upfront is therefore a major goal of the complex preoperative management of these patients. As surgical exploration without actual liver resection results in delayed systemic treatment among other disadvantages for the patient, we here aimed to identify preoperative predictors of non-resectablity in patients with pCCA. Within a large monocentric cohort of resected and surgically explored patients, age, PVE and arterial infiltration diagnosed on preoperative imaging were independent predictors of non-resectability for technical reasons (vascular infiltration without the possibility of reconstruction or resection extend larger than expected) and PVE, arterial infiltration and preoperative CA19-9 major predictors of non-resectability for oncological (distant lymph nodes, liver metastases and peritoneal carcinomatosis) and liver function (intraoperative diagnosis of cirrhosis) reasons. As technical resectability may only be assessed through explorative laparotomy, whereas oncological resectability and liver function could be adequately evaluated via laparoscopic exploration, our data suggests the routine utilization of diagnostic laparoscopy. This is especially relevant in patients displaying high-risk features for futile surgical exploration. Furthermore, survival analysis underlines the oncological impact of non-resectability and emphasizes the need for continuous efforts to improve resectability rates in these patients.
Although identified in separate analyses for oncological and technical reasons for non-resectability, preoperative risk factors such as old age, PVE, arterial infiltration, and elevated preoperative CA19-9 were commonly observed in patients who underwent laparotomy without subsequent resection.
PVE, as a tool to increase FLR in patients indicated for extended (mostly right-sided) hepatectomy, has been already used for several decades [23]. PVE decreases rates of post-hepatectomy liver failure (PHLF) and mortality and therefore increases resectability in patients with pCCA [24, 25]. Preoperative PVE as a predictor for non-resectability has not been identified in the literature yet. Interestingly, PVE was statistically associated with both non-resectability due to oncological/liver function and technical reasons. A potential explanation might be that patients who underwent PVE had larger and more complex tumors requiring trisectionectomy instead of standard right or left hepatectomy. Thereby, it should be noted that PVE induces a delay in surgery, which increases the chance of tumor progression.
Generally, pCCA with arterial infiltration can be treated in a well-selected patient group with acceptable perioperative complication rates and equivalent oncologic outcomes [2628]. However, our findings underline arterial infiltration as a still very relevant obstacle in the surgical treatment of pCCA and as a marker of an advanced tumor stage. In a study focusing mostly on patients excluded from surgical therapy/exploration based on preoperative imaging features, arterial involvement as a predictor for non-resectability has also been described by Ruys et al. in 2013 [29]. A current proof-of-principle study in a small cohort showed that hepatic artery involvement in a three-dimensional planning tool based on preoperative CT scans was a risk factor for an R1 or R2 resection [30]. Given those findings, arterial involvement should carefully be evaluated preoperatively [31].
Interestingly, patient age above 70 years was independently associated with non-resectability. Evidence on age as a predictive marker for non-resectability is limited, but patients with pCCA undergoing liver resection with arterial resection/reconstruction tend to be younger in general [26, 32]. Thus, especially in older patients complex vascular resections might be considered intraoperatively as non-resectable due to the associated morbidity. The same accounts for tumors that are intraoperatively assessed as larger than initially expected.
Lastly, elevated CA 19–9 levels showed statistical significance for non-resectability. The value of CA 19–9 as a predictor for resectability was previously demonstrated in single-center analyses based on Asian patients with one study also controlling the prognostic value for hyperbilirubinemia and cholangitis [33, 34]. However, both studies made no differentiation with respect to the reason of irresectability.
Another interesting fact is the irrelevance of Bismuth type IV for non-resectability. This type represents the most frequent in our cohort, implying the generally advanced tumor stage in the group. Our finding in general strengthens an aggressive therapeutical approach also in higher tumor stages.
During the study period, preoperative laparoscopy was not conducted as part of standard clinical management, and upfront laparotomy with consecutive resection in cases showing resectable in preoperative imaging was preferred. The few patients of the unresected cohort who underwent diagnostic laparoscopy (22/109) showed suspicious preoperative imaging findings or were scheduled for the staging procedure for various other reasons. Thus, these patients were excluded from the logistic regressions identifying risk factors for unnecessary laparotomies. However, the other 87 patients which are a notable amount compared to the resected cohort of 209 patients (87/296, 29.4%) during the study period, underwent an unsuccessful laparotomy. It is debatable whether technical non-resectability at the liver hilum or tumor extent of the bile duct can be reliably assessed using diagnostic laparoscopy (37.9%, 33/87). In contrast, peritoneal carcinomatosis, liver metastases or distant nodal metastases as well as impaired quality of the liver parenchyma are easily assessable by means of laparoscopy (59.8%, 52/87). The value of diagnostic laparoscopy was discussed controversially in the past. A systematic review and meta-analysis by Coelen and coworkers included 12 studies with overall 800 patients and showed a pooled sensitivity of 52.2% for diagnostic accuracy of staging laparoscopy in pCCA [35]. However, in the case of peritoneal metastases sensitivity was 80.7%, which seems sufficient to recommend diagnostic laparoscopy. Besides technical limitations, peritoneal carcinomatosis is the main reason for non-resectability in our cohort. In our analysis, we combined oncological reasons for non-resectability and intraoperatively diagnosed low-quality liver parenchyma during explorative laparotomy because both features are assessable by means of diagnostic laparoscopy. Considering the morbidity of almost 45% in the patient group that underwent explorative laparotomy without liver resection and a median hospitalization of 9 days as well as a certain delay in systemic therapy, our results give a strong argument for diagnostic laparoscopy as a staging tool in patients with pCCA. While conventional surgery is currently state-of-the-art for the treatment of pCCA, the integration of minimally invasive robotic liver surgery (MIRLS) could be a valuable tool in the future as new data and studies about this topic indicate [3638]. Given the first reports of robotic resections in the case of pCCA, it appears also to be feasible to assess resectability within the liver hilum by means of robotic surgery. This would also allow us to clarify technical resectablity in a minimal-invasive manner overcoming the technical limitations of laparoscopy in this regard.
Based on our findings, we propose routine diagnostic laparoscopy to avoid unnecessary laparotomies in patients with high-risk features, e.g., advanced age, preoperative PVE, arterial infiltration, and notable CA 19–9 elevation as these parameters appear strongly to be correlated with irresectability in pCCA patients.
From a theoretical perspective, modern non-invasive diagnostic tools might be considered to omit surgical exploration in some patients. In terms of liver function assessment, the LiMAx test has been used in several studies over the last decade to optimize general patient selection in different indications of liver resection [18, 39, 40]. However, studies focusing on pCCA patients and their specific clinical situation, e.g., after PVE, in the presence of cholangitis and cholestasis are currently not existing. The aforementioned clinical events and complications might interfere with modern liver function tests and therefore reduce the validity of the results for the detection of underlying liver fibrosis or cirrhosis. Based on the given results in other indications, an evaluation of the LiMAx test or other modern function tests appears worthwhile. Also, the role of positron emission tomography (PET), which might detect distant lymph node metastases, is considered controversial in pCCA and CCC in general. In a large systematic review and meta-analysis (2019) a sensitivity of 88.4% and specificity of 69.1% regarding lymph node invasion, and a sensitivity of 85.4% and specificity of 89.7% for distant metastasis was demonstrated for the use of 18F-fluorodeoxyglucose (18FDG) PET for staging in patients with biliary tract cancer. Worse results are reported for the primary tumor with a sensitivity of 91.7% and specificity of only 51.3% for 18FDG-PET [41]. While the PET-Technique might certainly offer a benefit for the intrahepatic subtype of CCA, it is debatable whether pCCA patients (who generally suffer from ongoing cholangitis) also benefit from preoperative PET.
As expected, patients undergoing surgical exploration (both laparoscopically and open) display worse survival than patients proceeding to liver resection (with a median CCS of 6 months compared to 32 months). These results are in accordance with previous studies and underline the superiority of oncological resection compared to palliative care in pCCA [34]. The notable benefit in survival is the main argument for our aggressive approach to the disease with a large amount of trisectionectomies and vessel reconstructions in our cohort. It is also a good argument to conduct surgery in the elderly after careful case-by-case evaluation of the individual fitness of the patient.
Fairly, some potential limitations must be mentioned according to this study. As a single-centered study, all results reflect the authors’ individual therapeutic approach to pCCA. Our strategies comprise an aggressive approach to the disease with vessel resection and reconstruction on demand. Thus, a subset of patients might not have been subjected to surgical exploration in the setting of a more conservative approach to surgical treatment of pCCA. Also, does our monocentric data warrant further validation by independent data sets? Further, the retrospective nature of the study does compromise the generalizability, does not allow accuracy as controlled prospective studies, and might introduce undetected bias. Admittedly, the presented data is based on an inclusion period of more than 10 years in which the role and technical possibilities of laparoscopy have substantially changed.
Considering the limitations, we identified advanced Age, PVE, and arterial infiltration in the preoperative imaging as independent predictors for non-resectability due to technical reasons in the setting of explorative laparotomy. PVE, arterial infiltration, and elevated CA19-9 are independent predictors for non-resectability due to oncological/liver function reasons. Critical evaluation and assessment of these mostly easily available parameters are recommended for better therapeutical pathways. Thus, diagnostic laparoscopy, especially in these high-risk situations, should be used to reduce the amount of explorative laparotomies without subsequent liver resection. Finally, our findings should further be assessed in future multicentric and prospective studies.

Declarations

This study was conducted in concordance with the requirements of the Institutional Review Board of the RWTH-Aachen University (EK 23–270) and the current version of the Declaration of Helsinki as well as the good clinical practice guidelines (ICH-GCP).

Competing interests

The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Klümpen HJ, et al. Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022;76(5):1109–21.CrossRefPubMed Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Klümpen HJ, et al. Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022;76(5):1109–21.CrossRefPubMed
2.
Zurück zum Zitat Bednarsch J, Czigany Z, Heij LR, Luedde T, Loosen SH, Dulk MD, et al. The prognostic role of in-hospital transfusion of fresh frozen plasma in patients with cholangiocarcinoma undergoing curative-intent liver surgery. Eur J Surg Oncol. 2022;48(3):604–14.CrossRefPubMed Bednarsch J, Czigany Z, Heij LR, Luedde T, Loosen SH, Dulk MD, et al. The prognostic role of in-hospital transfusion of fresh frozen plasma in patients with cholangiocarcinoma undergoing curative-intent liver surgery. Eur J Surg Oncol. 2022;48(3):604–14.CrossRefPubMed
3.
Zurück zum Zitat Neuhaus P, Thelen A, Jonas S, Puhl G, Denecke T, Veltzke-Schlieker W, et al. Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma. Ann Surg Oncol. 2012;19(5):1602–8.CrossRefPubMed Neuhaus P, Thelen A, Jonas S, Puhl G, Denecke T, Veltzke-Schlieker W, et al. Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma. Ann Surg Oncol. 2012;19(5):1602–8.CrossRefPubMed
4.
Zurück zum Zitat Neuhaus P, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg. 1999;230(6):808–18; discussion 19.CrossRefPubMedPubMedCentral Neuhaus P, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg. 1999;230(6):808–18; discussion 19.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Miyazaki M, Ito H, Nakagawa K, Ambiru S, Shimizu H, Shimizu Y, et al. Aggressive surgical approaches to hilar cholangiocarcinoma: hepatic or local resection? Surgery. 1998;123(2):131–6.CrossRefPubMed Miyazaki M, Ito H, Nakagawa K, Ambiru S, Shimizu H, Shimizu Y, et al. Aggressive surgical approaches to hilar cholangiocarcinoma: hepatic or local resection? Surgery. 1998;123(2):131–6.CrossRefPubMed
6.
Zurück zum Zitat Jonas S, Benckert C, Thelen A, Lopez-Hanninen E, Rosch T, Neuhaus P. Radical surgery for hilar cholangiocarcinoma. Eur J Surg Oncol. 2008;34(3):263–71.CrossRefPubMed Jonas S, Benckert C, Thelen A, Lopez-Hanninen E, Rosch T, Neuhaus P. Radical surgery for hilar cholangiocarcinoma. Eur J Surg Oncol. 2008;34(3):263–71.CrossRefPubMed
7.
Zurück zum Zitat Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234(4):507–17; discussion 17-9.CrossRefPubMedPubMedCentral Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234(4):507–17; discussion 17-9.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Massironi S, Pilla L, Elvevi A, Longarini R, Rossi RE, Bidoli P, et al. New and emerging systemic therapeutic options for advanced cholangiocarcinoma. Cells. 2020;9(3):688.CrossRefPubMedPubMedCentral Massironi S, Pilla L, Elvevi A, Longarini R, Rossi RE, Bidoli P, et al. New and emerging systemic therapeutic options for advanced cholangiocarcinoma. Cells. 2020;9(3):688.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.CrossRefPubMed Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.CrossRefPubMed
10.
Zurück zum Zitat Blechacz B. Cholangiocarcinoma: current knowledge and new developments. Gut Liver. 2017;11(1):13–26.CrossRefPubMed Blechacz B. Cholangiocarcinoma: current knowledge and new developments. Gut Liver. 2017;11(1):13–26.CrossRefPubMed
11.
Zurück zum Zitat Nagino M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg. 2013;258(1):129–40.CrossRefPubMed Nagino M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg. 2013;258(1):129–40.CrossRefPubMed
12.
Zurück zum Zitat Yilmaz S, Carr BI, Akbulut S. Can the limits of liver transplantation be expanded in perihilar cholangiocarcinoma? J Gastrointest Cancer. 2022;53(4):1104–12.CrossRefPubMed Yilmaz S, Carr BI, Akbulut S. Can the limits of liver transplantation be expanded in perihilar cholangiocarcinoma? J Gastrointest Cancer. 2022;53(4):1104–12.CrossRefPubMed
13.
Zurück zum Zitat Dondossola D, Ghidini M, Grossi F, Rossi G, Foschi D. Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. World J Gastroenterol. 2020;26(25):3542–61.CrossRefPubMedPubMedCentral Dondossola D, Ghidini M, Grossi F, Rossi G, Foschi D. Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. World J Gastroenterol. 2020;26(25):3542–61.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Cillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt HJ, et al. Surgery for cholangiocarcinoma. Liver Int. 2019;39 Suppl 1(Suppl Suppl 1):143–55.CrossRefPubMed Cillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt HJ, et al. Surgery for cholangiocarcinoma. Liver Int. 2019;39 Suppl 1(Suppl Suppl 1):143–55.CrossRefPubMed
15.
Zurück zum Zitat Pratt CG, Whitrock JN, Shah SA, Fong ZV. How to determine unresectability in hilar cholangiocarcinoma. Surg Clin North Am. 2024;104(1):197–214.CrossRefPubMed Pratt CG, Whitrock JN, Shah SA, Fong ZV. How to determine unresectability in hilar cholangiocarcinoma. Surg Clin North Am. 2024;104(1):197–214.CrossRefPubMed
16.
Zurück zum Zitat Lurje G, Bednarsch J, Czigany Z, Lurje I, Schlebusch IK, Boecker J, et al. The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2019;45(8):1468–78.CrossRefPubMed Lurje G, Bednarsch J, Czigany Z, Lurje I, Schlebusch IK, Boecker J, et al. The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2019;45(8):1468–78.CrossRefPubMed
17.
Zurück zum Zitat Bednarsch J, Czigany Z, Lurje I, Tacke F, Strnad P, Ulmer TF, et al. Left- versus right-sided hepatectomy with hilar en-bloc resection in perihilar cholangiocarcinoma. HPB (Oxford). 2020;22(3):437–44.CrossRefPubMed Bednarsch J, Czigany Z, Lurje I, Tacke F, Strnad P, Ulmer TF, et al. Left- versus right-sided hepatectomy with hilar en-bloc resection in perihilar cholangiocarcinoma. HPB (Oxford). 2020;22(3):437–44.CrossRefPubMed
18.
Zurück zum Zitat Stockmann M, Lock JF, Malinowski M, Niehues SM, Seehofer D, Neuhaus P. The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB (Oxford). 2010;12(2):139–46.CrossRefPubMed Stockmann M, Lock JF, Malinowski M, Niehues SM, Seehofer D, Neuhaus P. The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB (Oxford). 2010;12(2):139–46.CrossRefPubMed
19.
Zurück zum Zitat Bednarsch J, Kather J, Tan X, Sivakumar S, Cacchi C, Wiltberger G, et al. Nerve fibers in the tumor microenvironment as a novel biomarker for oncological outcome in patients undergoing surgery for perihilar cholangiocarcinoma. Liver cancer. 2021;10(3):260–74.CrossRefPubMedPubMedCentral Bednarsch J, Kather J, Tan X, Sivakumar S, Cacchi C, Wiltberger G, et al. Nerve fibers in the tumor microenvironment as a novel biomarker for oncological outcome in patients undergoing surgery for perihilar cholangiocarcinoma. Liver cancer. 2021;10(3):260–74.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Bednarsch J, Tan X, Czigany Z, Liu D, Lang SA, Sivakumar S, et al. The presence of small nerve fibers in the tumor microenvironment as predictive biomarker of oncological outcome following partial hepatectomy for intrahepatic cholangiocarcinoma. Cancers (Basel). 2021;13(15):3661.CrossRefPubMed Bednarsch J, Tan X, Czigany Z, Liu D, Lang SA, Sivakumar S, et al. The presence of small nerve fibers in the tumor microenvironment as predictive biomarker of oncological outcome following partial hepatectomy for intrahepatic cholangiocarcinoma. Cancers (Basel). 2021;13(15):3661.CrossRefPubMed
21.
Zurück zum Zitat Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–73.CrossRefPubMed Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–73.CrossRefPubMed
22.
Zurück zum Zitat Akbulut S, Sahin TT, Yilmaz S. Comment on pediatric living donor liver transplantation decade progress in Shanghai: characteristics and risks factors of mortality. World J Gastroenterol. 2020;26(30):4564–6.CrossRefPubMedPubMedCentral Akbulut S, Sahin TT, Yilmaz S. Comment on pediatric living donor liver transplantation decade progress in Shanghai: characteristics and risks factors of mortality. World J Gastroenterol. 2020;26(30):4564–6.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Palavecino M, Abdalla EK, Madoff DC, Vauthey JN. Portal vein embolization in hilar cholangiocarcinoma. Surg Oncol Clin N Am. 2009;18(2):257–67, viii.CrossRefPubMed Palavecino M, Abdalla EK, Madoff DC, Vauthey JN. Portal vein embolization in hilar cholangiocarcinoma. Surg Oncol Clin N Am. 2009;18(2):257–67, viii.CrossRefPubMed
24.
Zurück zum Zitat Narula N, Aloia TA. Portal vein embolization in extended liver resection. Langenbecks Arch Surg. 2017;402(5):727–35.CrossRefPubMed Narula N, Aloia TA. Portal vein embolization in extended liver resection. Langenbecks Arch Surg. 2017;402(5):727–35.CrossRefPubMed
25.
Zurück zum Zitat Olthof PB, Aldrighetti L, Alikhanov R, Cescon M, Groot Koerkamp B, Jarnagin WR, et al. Portal vein embolization is associated with reduced liver failure and mortality in high-risk resections for perihilar cholangiocarcinoma. Ann Surg Oncol. 2020;27(7):2311–8.CrossRefPubMedPubMedCentral Olthof PB, Aldrighetti L, Alikhanov R, Cescon M, Groot Koerkamp B, Jarnagin WR, et al. Portal vein embolization is associated with reduced liver failure and mortality in high-risk resections for perihilar cholangiocarcinoma. Ann Surg Oncol. 2020;27(7):2311–8.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Schimizzi GV, Jin LX, Davidson JTT, Krasnick BA, Ethun CG, Pawlik TM, et al. Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford). 2018;20(4):332–9.CrossRefPubMed Schimizzi GV, Jin LX, Davidson JTT, Krasnick BA, Ethun CG, Pawlik TM, et al. Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford). 2018;20(4):332–9.CrossRefPubMed
27.
Zurück zum Zitat Matsuyama R, Mori R, Ota Y, Homma Y, Kumamoto T, Takeda K, et al. Significance of vascular resection and reconstruction in surgery for hilar cholangiocarcinoma: with special reference to hepatic arterial resection and reconstruction. Ann Surg Oncol. 2016;23(Suppl 4):475–84.CrossRefPubMed Matsuyama R, Mori R, Ota Y, Homma Y, Kumamoto T, Takeda K, et al. Significance of vascular resection and reconstruction in surgery for hilar cholangiocarcinoma: with special reference to hepatic arterial resection and reconstruction. Ann Surg Oncol. 2016;23(Suppl 4):475–84.CrossRefPubMed
28.
Zurück zum Zitat Wang Y, Lu J. Short-term and long-term clinical outcomes of combined major vessel resection for hilar cholangiocarcinoma: a propensity score analysis. Ann Surg Treat Res. 2023;105(5):319–32.CrossRefPubMedPubMedCentral Wang Y, Lu J. Short-term and long-term clinical outcomes of combined major vessel resection for hilar cholangiocarcinoma: a propensity score analysis. Ann Surg Treat Res. 2023;105(5):319–32.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Ruys AT, Busch OR, Rauws EA, Gouma DJ, van Gulik TM. Prognostic impact of preoperative imaging parameters on resectability of hilar cholangiocarcinoma. HPB Surg. 2013;2013:657309.CrossRefPubMedPubMedCentral Ruys AT, Busch OR, Rauws EA, Gouma DJ, van Gulik TM. Prognostic impact of preoperative imaging parameters on resectability of hilar cholangiocarcinoma. HPB Surg. 2013;2013:657309.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Zhang JZ, Yang CX, Gao S, Bu JF, Li QQ, Wang HL, et al. Three-dimensional visualization and evaluation of hilar cholangiocarcinoma resectability and proposal of a new classification. World J Surg Oncol. 2023;21(1):239.CrossRefPubMedPubMedCentral Zhang JZ, Yang CX, Gao S, Bu JF, Li QQ, Wang HL, et al. Three-dimensional visualization and evaluation of hilar cholangiocarcinoma resectability and proposal of a new classification. World J Surg Oncol. 2023;21(1):239.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Ji GW, Zhang YD, Wang K, Zhang H, Shao ZC, Jiang WJ, et al. Short- and long-term outcomes of middle hepatic vein-oriented hepatectomy for advanced perihilar cholangiocarcinoma. J Surg Oncol. 2018;118(3):446–54.CrossRefPubMed Ji GW, Zhang YD, Wang K, Zhang H, Shao ZC, Jiang WJ, et al. Short- and long-term outcomes of middle hepatic vein-oriented hepatectomy for advanced perihilar cholangiocarcinoma. J Surg Oncol. 2018;118(3):446–54.CrossRefPubMed
33.
Zurück zum Zitat Hu HJ, Mao H, Tan YQ, Shrestha A, Ma WJ, Yang Q, et al. Clinical value of preoperative serum CA 19–9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma. Springerplus. 2016;5:551.CrossRefPubMedPubMedCentral Hu HJ, Mao H, Tan YQ, Shrestha A, Ma WJ, Yang Q, et al. Clinical value of preoperative serum CA 19–9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma. Springerplus. 2016;5:551.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Peng D, Lu J, Hu H, Li B, Ye X, Cheng N. Lymphocyte to monocyte ratio predicts resectability and early recurrence of bismuth-corlette type IV hilar cholangiocarcinoma. J Gastrointest Surg. 2020;24(2):330–40.CrossRefPubMed Peng D, Lu J, Hu H, Li B, Ye X, Cheng N. Lymphocyte to monocyte ratio predicts resectability and early recurrence of bismuth-corlette type IV hilar cholangiocarcinoma. J Gastrointest Surg. 2020;24(2):330–40.CrossRefPubMed
35.
Zurück zum Zitat Coelen RJ, Ruys AT, Besselink MG, Busch OR, van Gulik TM. Diagnostic accuracy of staging laparoscopy for detecting metastasized or locally advanced perihilar cholangiocarcinoma: a systematic review and meta-analysis. Surg Endosc. 2016;30(10):4163–73.CrossRefPubMedPubMedCentral Coelen RJ, Ruys AT, Besselink MG, Busch OR, van Gulik TM. Diagnostic accuracy of staging laparoscopy for detecting metastasized or locally advanced perihilar cholangiocarcinoma: a systematic review and meta-analysis. Surg Endosc. 2016;30(10):4163–73.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Lopez-Lopez V, Esquer IS, Valles PG, Conesa AL, Brusadin R, Navarro A, et al. Robotic perihilar cholangiocarcinoma: a step forward in the challenge of minimally invasive liver surgery. Ann Surg Oncol. 2024;31:1836–7. Lopez-Lopez V, Esquer IS, Valles PG, Conesa AL, Brusadin R, Navarro A, et al. Robotic perihilar cholangiocarcinoma: a step forward in the challenge of minimally invasive liver surgery. Ann Surg Oncol. 2024;31:1836–7.
37.
Zurück zum Zitat Cillo U, D’Amico FE, Furlanetto A, Perin L, Gringeri E. Robotic hepatectomy and biliary reconstruction for perihilar cholangiocarcinoma: a pioneer western case series. Updates Surg. 2021;73(3):999–1006.CrossRefPubMedPubMedCentral Cillo U, D’Amico FE, Furlanetto A, Perin L, Gringeri E. Robotic hepatectomy and biliary reconstruction for perihilar cholangiocarcinoma: a pioneer western case series. Updates Surg. 2021;73(3):999–1006.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Di Benedetto F, Magistri P, Catellani B, Guerrini GP, Di Sandro S. Robotic left hepatectomy with en bloc caudatectomy and multiple biliary anastomosis for perihilar cholangiocarcinoma. Ann Surg Oncol. 2023;30(5):2832–3.CrossRefPubMed Di Benedetto F, Magistri P, Catellani B, Guerrini GP, Di Sandro S. Robotic left hepatectomy with en bloc caudatectomy and multiple biliary anastomosis for perihilar cholangiocarcinoma. Ann Surg Oncol. 2023;30(5):2832–3.CrossRefPubMed
39.
Zurück zum Zitat Rahimli M, Perrakis A, Gumbs AA, Andric M, Al-Madhi S, Arend J, et al. The LiMAx test as selection criteria in minimally invasive liver surgery. J Clin Med. 2022;11(11):3018.CrossRefPubMedPubMedCentral Rahimli M, Perrakis A, Gumbs AA, Andric M, Al-Madhi S, Arend J, et al. The LiMAx test as selection criteria in minimally invasive liver surgery. J Clin Med. 2022;11(11):3018.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Anger F, Klein I, Löb S, Wiegering A, Singh G, Sperl D, et al. Preoperative liver function guiding HCC resection in normal and cirrhotic liver. Visc Med. 2021;37(2):94–101.CrossRefPubMed Anger F, Klein I, Löb S, Wiegering A, Singh G, Sperl D, et al. Preoperative liver function guiding HCC resection in normal and cirrhotic liver. Visc Med. 2021;37(2):94–101.CrossRefPubMed
41.
Zurück zum Zitat Lamarca A, Barriuso J, Chander A, McNamara MG, Hubner RA, ÓReilly D, et al. (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. J Hepatol. 2019;71(1):115–29.CrossRefPubMed Lamarca A, Barriuso J, Chander A, McNamara MG, Hubner RA, ÓReilly D, et al. (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. J Hepatol. 2019;71(1):115–29.CrossRefPubMed
Metadaten
Titel
Preoperative predictors for non-resectability in perihilar cholangiocarcinoma
verfasst von
Carlos Constantin Otto
Anna Mantas
Lara Rosaline Heij
Daniel Heise
Maxime Dewulf
Sven Arke Lang
Tom Florian Ulmer
Edgar Dahl
Philipp Bruners
Ulf Peter Neumann
Jan Bednarsch
Publikationsdatum
01.12.2024
Verlag
BioMed Central
Erschienen in
World Journal of Surgical Oncology / Ausgabe 1/2024
Elektronische ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-024-03329-1

Weitere Artikel der Ausgabe 1/2024

World Journal of Surgical Oncology 1/2024 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.